IGC Pharma has announced the expansion of its Phase 2 CALMA clinical trial to include a prominent research center in Colombia, known for its expertise in Alzheimer’s disease. This addition aims to increase the genetic diversity of trial participants and enhance the overall study quality.
The inclusion of the Colombian site is expected to support the company’s goal of advancing its Alzheimer’s treatment development and achieving key data milestones by 2026.
**Why this matters**
Expanding the trial to a globally recognized center in Colombia allows for a more diverse participant pool, which can improve the reliability and applicability of the trial results. This step also underscores the importance of inclusive research practices in developing effective treatments for Alzheimer’s disease.
Source: NewsData